Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Stock picks for a tough month
07:19pm, Friday, 02'nd Sep 2022
Kevin Simpson of Capital Wealth Planning and Andrew Graham of Jackson Square Capital join Becky Quick and the 'CNBC Special: Back to Business' to reveal their favorite stock picks.
Final Trades: CME, Abbvie & more
01:58pm, Thursday, 01'st Sep 2022
The "Halftime Report" traders give their top picks to watch for the second half.
3 Dividend Stocks to Buy in September for Passive Income Generation
10:51am, Thursday, 01'st Sep 2022 The Motley Fool
Buying these stocks now could lead to dividend payments that grow for the rest of your life.
Top 2 dividend shares to navigate stock market in H2, 2022
08:53am, Thursday, 01'st Sep 2022
Yield is not the be-all and end-all when picking out the best dividend stocks, especially in a volatile market like
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
04:53pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplasti
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Amgen (AMGN) Outperforms Industry Year to Date: What's Next?
03:22pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
01:00pm, Monday, 29'th Aug 2022 Zacks Investment Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
11:43am, Monday, 29'th Aug 2022 Zacks Investment Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:32am, Monday, 29'th Aug 2022
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Why Dividend Growth Stocks Should Be Part of Your Retirement Plan
02:00pm, Friday, 26'th Aug 2022 The Motley Fool
Growing your passive income can make it much easier to live off your investments during your retirement years.
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
01:09pm, Friday, 26'th Aug 2022 Zacks Investment Research
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Why Dividend Growth Stocks Should Be Part of Your Retirement Plan
10:00am, Friday, 26'th Aug 2022
Growing your passive income can make it much easier to live off your investments during your retirement years.
Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
01:05am, Friday, 26'th Aug 2022
Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs.
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
05:12pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
